A biotech incubator identifying and evaluating promising pre-clinical assets in Australian universities and advancing them to clinical trials.
ProtoAxiom has assembled a centralized management and R&D team that works closely with prolific Australian scientists and Australian universities to develop early-stage biotech assets into investable companies. The team identifies therapeutics and drug discovery platforms with best-in-class scientific and commercial potential, before in-licensing them into a central incubator that conducts IND-enabling studies and facilitates company formation. Successful platforms and assets are spun out as clinical-stage companies, bridging the significant gap between Australia’s best academic IP and biotech investors.
ProtoAxiom has assembled a centralized management and R&D team that works closely with prolific Australian scientists and Australian universities to develop early-stage biotech assets into investable companies. The team identifies therapeutics and drug discovery platforms with best-in-class scientific and commercial potential, before in-licensing them into a central incubator that conducts IND-enabling studies and facilitates company formation. Successful platforms and assets are spun out as clinical-stage companies, bridging the significant gap between Australia’s best academic IP and biotech investors.
Total raised: $20.25M
Investors 1
| Date | Name | Website |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.08.2024 | Series B | $20M | - |
| 21.05.2024 | Grant | $250K | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.07.2026 | AdvanCell Closes $315 Million Series D | BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscribed and upsized $315 million Series D financing. >> Click here for more funding data on AdvanCell >> To export AdvanCel... |
| 15.07.2026 | AdvanCell Closes $315 Million Series D Financing To Advance Targeted Alpha Therapies | AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, announced the closing of an oversubscribed and upsized $315 million Series D financing. The round was led by Ally Bridge Group and co-le... |
| 15.07.2026 | AdvanCell Closes US $315M in Series D Funding | AdvanCell, a Boston, MA- and Brisbane, Australia-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised US $315M Series D in funding. The round was led by Ally Bridge Group and Alpha Wave, al... |
| 05.06.2025 | Proto Axiom and St Vincent's Curran Foundation join forces to host Australia's largest medical pitch day | SYDNEY, June 5, 2025 /PRNewswire/ -- Proto Axiom, Australia's leading biotech incubator, and St Vincent's Curran Foundation unite to launch Challenger Pitch for Health, the nation's largest medical and biotech pitch event, in Sydney in Marc... |
| 24.10.2024 | Pioneering Healthcare Innovations: Australia’s Bright Future in Medical Research | Australia is making waves in the healthcare sector. The recent Challenger Summit and a groundbreaking collaboration between PredxBio and the University of Queensland highlight the nation’s commitment to advancing medical research. These eve... |
| 23.10.2024 | Australia's Healthcare Innovators in Stroke and Paediatric Care Honoured at 2024 Challenger Summit | Life sciences investor Proto Axiom awards $250,000 in prizes at inaugural Summit SYDNEY, Oct. 23, 2024 /PRNewswire/ -- The 2024 Challenger Summit concluded with two visionary researchers recognised for their groundbreaking contributions to ... |
| 13.08.2024 | Australian biotech incubator Proto Axiom announces $20M Series B first close | $20M unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at $90M SYDNEY, Aug. 13, 2024 /PRNewswire/ -- Proto Axiom, the Australian biomedical technology incubator has today announced a $20 million first close of... |
| 13.08.2024 | Deals in brief: HealthCred and Vayana raise funding, Antler announces final close of second Southeast Asia fund, three China deals, and more | HealthCred raises USD 1.2 million in seed round HealthCred, an Indian B2B healthcare financing startup, has raised USD 1.2 million in a seed funding round led by Antler India, TRTL VC, DeVC, iSeedVC, and AngelList India, with participation ... |
| 21.05.2024 | Proto Axiom Launches The Challenger Summit: Australia's Premier Biotech Pitch-Event with over $250,000 in Grant Financing | SYDNEY, May 21, 2024 /PRNewswire/ -- Proto Axiom, Australia's first true biotech incubator, is thrilled to announce the launch of The Challenger Summit. The Challenger Summit will provide a unique platform for researchers to showcase their ... |
| 18.04.2023 | Proto Axiom, Australian biomedical technology incubator received $15 M in Series A funding | Following its initial raise of $10 million last September, the Australian biomedical technology incubator Proto Axiom announced a second round of financing for $5 million. According to a statement from Proto Axiom, this is the biotechnology... |
Show more